OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing…
| Métrica | OKYO | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.4% | — |
| Operating Margin | — | -34.4% | — |
| Net Margin | — | -32.5% | — |
| FCF Margin | — | -12.6% | — |
| ROE | — | -39.2% | — |
| ROA | — | -30.9% | — |
| Current Ratio | — | 2.73 | — |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | — | — |
| ✗Flujo de caja operativo positivo | — | −$9M |
| ✗Rentabilidad sobre activos al alza | — | -1091.7% |
| –Caja operativa/activos supera al ROA | — | — |
| –Menos deuda a largo plazo | — | — |
| ✗Mejor liquidez (ratio corriente) | — | 0.21 |
| ✗Sin aumentar el nº de acciones | — | 30M |
| –Margen bruto al alza | — | — |
| –Rotación de activos al alza | — | — |
OKYO Pharma Ltd cotiza a 1.41 USD y tiene una capitalización bursátil de $74M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud